NCT04932005 - A Study of DZD2269 in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

April 12, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

DZD2269

Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.

DRUG

placebo

Part A: A single oral dose. Part C: Twice daily dosing for 7 days.

Trial Locations (1)

Frontage Clinical Service 200 Meadowlands Parkway, Secaucus